The store will not work correctly when cookies are disabled.
1-(2,3-difluorophenyl)-N-(1-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl)cyclopropanecarboxamide
ID: ALA5188173
PubChem CID: 168279371
Max Phase: Preclinical
Molecular Formula: C18H13F3N4O
Molecular Weight: 358.32
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(Nc1ccn(-c2cncc(F)c2)n1)C1(c2cccc(F)c2F)CC1
Standard InChI: InChI=1S/C18H13F3N4O/c19-11-8-12(10-22-9-11)25-7-4-15(24-25)23-17(26)18(5-6-18)13-2-1-3-14(20)16(13)21/h1-4,7-10H,5-6H2,(H,23,24,26)
Standard InChI Key: OGYKUWFIKQOOPI-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 29 0 0 0 0 0 0 0 0999 V2000
6.7191 -22.4563 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0134 -22.0477 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0124 -22.8632 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4980 -23.2445 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.4968 -24.0641 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2049 -24.4730 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9145 -24.0636 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9117 -23.2409 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2031 -22.8357 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6175 -22.8272 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.3653 -23.1567 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.9098 -22.5473 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4985 -21.8411 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6999 -22.0142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.7228 -22.6297 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.2007 -21.9668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8655 -21.2215 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.4915 -21.3862 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.3024 -21.4705 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7801 -20.8084 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.4449 -20.0621 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.6274 -19.9820 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.1534 -20.6450 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2047 -25.2902 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
7.6364 -22.2163 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
8.5931 -20.8911 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2 1 1 0
3 2 1 0
1 3 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
10 11 1 0
11 12 2 0
12 13 1 0
13 14 2 0
14 10 1 0
8 10 1 0
12 15 1 0
15 16 1 0
16 2 1 0
16 17 2 0
2 18 1 0
18 19 2 0
19 20 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 18 1 0
6 24 1 0
19 25 1 0
20 26 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 358.32 | Molecular Weight (Monoisotopic): 358.1041 | AlogP: 3.35 | #Rotatable Bonds: 4 |
Polar Surface Area: 59.81 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 11.17 | CX Basic pKa: 2.39 | CX LogP: 3.57 | CX LogD: 3.57 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.78 | Np Likeness Score: -1.96 |
References
1. Come JH, Senter TJ, Clark MP, Court JJ, Gale-Day Z, Gu W, Krueger E, Liang J, Morris M, Nanthakumar S, O'Dowd H, Maltais F, Iyer G, Andreassi J, Boucher C, Considine T, Moody CS, Taylor W, Mohanty AK, Huang Y, Zuccola H, Coll J, Bonanno KC, Gagnon KJ, Gan L, Lu F, Gao H, Chakilam A, Engtrakul J, Song B, Crawford D, Doyle E, Kramer T, Vought B, Phillips J, Kemper R, Sanders M, Swett R, Furey B, Winquist R, Bunnage ME, Jackson KL, Charifson PS, Magavi SS.. (2021) Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1., 64 (24.0): [PMID:34748351] [10.1021/acs.jmedchem.1c00944] |